Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.37 |
| ▸ | PI4KA | P42356 | 4/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8552177 | 0.86 | LIMK1 (0.34) | LIMK1 | |
| SCHEMBL28145458 | 0.86 | LIMK1 (0.33) | LIMK1LMNA | |
| SCHEMBL27099013 | 0.82 | PDPK1 (0.36) | LIMK1ALDH1A1CYP2C19 | |
| Purine SCHEMBL18132338 | 0.78 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBXDH | |
| Purine SCHEMBL18132340 | 0.75 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL6309439 | 0.74 | NOS3 (0.33) | ALDH1A1 | |
| SCHEMBL8856017 | 0.71 | CHEK1 (0.31) | ALDH1A1 | |
| Water SCHEMBL8865234 | 0.71 | ALDH1A1 (0.33) | ALDH1A1CYP2C19 | |
| SCHEMBL28190077 | 0.70 | MAPT (0.31) | LMNA | |
| SCHEMBL8928297 | 0.70 | MEN1 (0.33) | LIMK1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | claimed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4504959-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2024259563-A1 | MULTIPLEX RT-PCR AMPLIFICATION METHOD AND USE THEREOF | 深圳华大智造科技股份有限公司 | 2024-12-26 | — | — | WO | claimed |
| WO-2024259564-A1 | METHOD FOR CONSTRUCTING TARGETED LIBRARY BY ONE-STEP PROCESS, AND USE THEREOF | 深圳华大智造科技股份有限公司 | 2024-12-26 | — | — | WO | claimed |
| US-12084715-B1 | Methods and systems for reducing artifactual antisense products | 10X GENOMICS, INC. (US) | 2024-09-10 | — | — | US | claimed |
| CN-111235245-B | Method of | 牛津纳米孔科技公开有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-117512078-A | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2024-02-06 | — | — | CN | claimed |
| CN-109804083-B | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2023-11-03 | — | — | CN | claimed |
| US-20040023220-A1 | Integrated method for PCR cleanup and oligonucleotide removal | APPLIED BIOSYSTEMS, LLC | 2004-02-05 | — | — | US | claimed |
| WO-2004009851-A2 | METHOD FOR PCR CLEANUP AND OLIGONUCLEOTIDE REMOVAL | APPLERA CORPORATION (US) | 2004-01-29 | — | — | WO | claimed |
| WO-2003012100-A2 | METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS | DIREVO BIOTECH AG (DE) | 2003-02-13 | — | — | WO | claimed |
| EP-1281757-A1 | Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids | Direvo Biotech AG (DE) | 2003-02-05 | — | — | EP | claimed |
| EP-0706581-A4 | DNA PROFILES AS AN INDICATOR OF CELLULAR REDOX POTENTIAL AND CANCER RISK | PACIFIC NORTHWEST RESEARCH FOU (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0719265-B1 | NUCLEOSIDE DERIVATIVES, METHODS FOR THE MANUFACTURE THEREOF AND SPECIFIC POLYCLONAL AND MONOCLONAL ANTIBODIES OF SAID DERIVATIVES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1998-12-02 | — | — | EP | claimed |
| US-5665553-A | Methods for determining and modulating cellular redox potential and genotoxic states | PACIFIC NORTHWEST RESEARCH FOUNDATION (US) | 1997-09-09 | — | — | US | claimed |
| US-5601981-A | ASSAYING DNA FROM TEST SPECIMEN FOR CONCENTRATION OF RING-OPENED AND HYDROXYL DERIVATIVES, COMPARING, WHEREIN REDUCTIVE CELLULAR REDOX POTENTIAL EXISTS WHEN FORMATION OF RING-OPENED OVER HYDROXYL DERIVATIVES IS FAVORED | PACIFIC NORTHWEST RESEARCH FOUNDATION (US) | 1997-02-11 | — | — | US | claimed |
| EP-0706581-A1 | DNA PROFILES AS AN INDICATOR OF CELLULAR REDOX POTENTIAL AND CANCER RISK | PACIFIC NORTHWEST RESEARCH FOUNDATION (US) | 1996-04-17 | — | — | EP | claimed |
| WO-1994025626-A1 | DNA PROFILES AS AN INDICATOR OF CELLULAR REDOX POTENTIAL AND CANCER RISK | PACIFIC NORTHWEST RESEARCH FOUNDATION (US) | 1994-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | PNP, NT5C3B, UNG | LIMK1 4547/4885PI4KA 747/4885PI4K2B 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.